International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationInitial Stage Affects Survival Even After Complete Pathologic Remission is Achieved in Locally Advanced Esophageal Cancer: Analysis of 70 Patients With Pathologic Major Response After Preoperative Chemoradiotherapy
Introduction
Concurrent chemoradiotherapy (CRT) followed by esophagectomy has become a standard treatment option in patients with operable esophageal cancer 1, 2, 3, 4, 5. In our institution, all patients with operable Stage ≥II esophageal cancer undergo preoperative CRT 6, 7, 8, 9. We have previously reported that the 5-year overall survival (OS) rate of patients who do and do not achieve a pathologic complete response (PCR) was significantly different (57% and 33%, respectively) (10). Several studies have also demonstrated that pathologic complete responses to preoperative CRT are important predictors of survival (11). However, some patients who achieve PCR subsequently experience tumor recurrence or death, whereas few studies have assessed the prognostic factors for survival or recurrence in these patients.
It is well known that the degree of histomorphologic regression after preoperative CRT correlates with clinical outcome of patients 12, 13. However, several researchers have reported that the OS of patients who achieved major histologic response after preoperative CRT was similar to the survival of patients who achieved PCR 14, 15, 16. We have found that some patients who achieved significant pathologic regression after preoperative CRT retained residual small tumor foci, with these patients designated as having microscopic residual disease (MRD) 6, 17. Comparative analysis of clinical outcomes of patients that have achieved PCR or MRD has not yet been reported. We hypothesized that although OS may be similar in patients with PCR and MRD, the recurrence rate or recurrence-free survival (RFS) may differ between these two groups of patients.
We therefore analyzed clinical outcomes in patients with operable esophageal cancer who achieved pathologic major response (PMR, either PCR or MRD) in three clinical trials of preoperative CRT. We sought to determine the factors that predict survival and recurrence among patients with PMR, and have assessed whether the recurrence rate and survival differed between patients who achieved PCR and had MRD after preoperative CRT.
Section snippets
Patients
Beginning in March 1993, we performed three prospective clinical trials on a total of 268 patients with locally advanced but resectable esophageal cancer 6, 7, 8, 9, 10. Of these 268 patients, 180 patients were treated with preoperative CRT, including 129 who also underwent esophagectomy. Of the 129 patients, 58 patients achieved PCR and 17 had MRD; of these 75 patients, 5 (6.6%) patients died of perioperative mortality and were excluded from the analysis of recurrence and survival. Ultimately,
Patient and treatment characteristics
Fifty-three patients who achieved PCR at the time of surgery and 17 patients who had MRD were enrolled in the analysis. Patient characteristics are summarized in Table 1. The 70 patients consisted of 60 men and 10 women, with a median age of 63 years (range, 43–71 years). Histologically, all of the primary tumors were squamous cell carcinomas. Forty-two patients (60%) had Stage II disease and 28 patients (40%) had Stage III carcinomas. Fifty-four patients (77%) underwent EUS and 35 patients
Discussion
Although uncertainty remains regarding whether multimodal therapy is superior to surgery in patients with esophageal cancer, we have found that subgroups of patients who have achieved PMR clearly benefit from preoperative CRT. Although PCR may be an excellent predictor of outcome, not all patients have the same outcome. To identify the prognostic factors for tumor recurrence and patient survival, we retrospectively reviewed outcomes in 70 patients who had achieved PMR after preoperative CRT.
References (25)
- et al.
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial
Lancet Oncol
(2005) - et al.
A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma
Ann Oncol
(2004) - et al.
Treatment outcome and recursive partitioning analysis-based prognostic factors in patients with esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy
Int J Radiat Oncol Biol Phys
(2008) - et al.
FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer
Int J Radiat Oncol Biol Phys
(2005) - et al.
Accuracy of pathologic examination in detection of complete response after chemoradiation for esophageal cancer
Am J Surg
(2007) - et al.
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma
N Engl J Med
(1996) - et al.
Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus
N Engl J Med
(1997) - et al.
Controversies in the multimodality management of locally advanced esophageal cancer: Evidence-based review of surgery alone and combined-modality therapy
Ann Surg Oncol
(2004) - et al.
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma
J Clin Oncol
(2001) Esophageal cancer; multimodality approach
Cancer Res Treatment
(2003)
Efficacy of neoadjuvant chemoradiotherapy in resectable esophageal squamous cell carcinoma—a single institutional study
Acta Oncol
A phase II trial of preoperative one cycle of induction chemotherapy [capecitibine (CAP), CDDP] followed by concurrent chemoradiation (CRT) in patients (pts) with resectable esophageal cancer
J Clin Oncol
Cited by (23)
Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an international Delphi consensus survey
2021, Human PathologyCitation Excerpt :Irrespective of the system used, the survival benefit of complete response contra no response after neoadjuvant treatment is noncontroversial and represents a well-defined prognostic marker [5,15–17]. However, there is currently no consensus regarding the optimal TRG system, and the issue is still intensively discussed [4,5,9–13,18,19]. In a recently published Delphi study regarding TRG in gastric adenocarcinomas, a panel of pathologists specialized in gastric pathology concluded that a 4-tiered system for the primary tumor combined with a 3-tiered system for metastatic LNs would be an optimal TRG system [20].
Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment
2019, European Journal of Surgical OncologyCitation Excerpt :Trimodality treatment with neoadjuvant concurrent chemoradiotherapy (CCRT) followed by esophagectomy offers a convincing survival benefit [2,3] and is becoming the standard of care for locally advanced esophageal cancer, especially for esophageal squamous cell carcinoma (ESCC) [2]. Neoadjuvant CCRT yields a pathological complete response (pCR) in 18–52% of patients undergoing trimodality therapy and a significantly higher 5-year survival rate in patients with pCR than in patients with residual disease [4–7]. However, 14–39% of patients achieving pCR eventually experience recurrences, with the majority (44% up to 90%) of relapses occurring at distant sites [4,5,7–11].
Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgery
2019, Journal of Thoracic and Cardiovascular SurgeryHas integrated 18F FDG PET/CT improved staging, reduced early recurrence or increased survival in oesophageal cancer?
2015, SurgeonCitation Excerpt :In the operative group, we have shown that in this cohort of patients the introduction of staging PET/CT has not had a significant effect on survival. With a higher proportion of patients undergoing neo-adjuvant chemotherapy it might be expect that those in the PET/CT group will have an improved survival because of this30–32 but this was not the case. This supports the conclusion of the most recent Cochrane review of the use of ‘Preoperative chemotherapy for resectable thoracic esophageal cancer’.33
Squamous Cell Carcinoma of the Esophagus: Treat With How Many Modalities?
2009, Seminars in OncologyCitation Excerpt :A recent retrospective review of one institution's series of 61 esophageal cancer patients staged with PET/CT concluded that, while PET/CT can indicate response of locoregional disease to adjuvant therapy, there was no relationship between decrease of the elevated PET standardized uptake value in presumed tumor areas and disease-free survival, overall survival, or local control.9 Lastly, a recent analysis of prognostic factors in patients with esophageal cancers concluded that even when pathological response is complete, initial clinical stage is independently correlated with survival and risk of local recurrence, arguing that there might be few patients with T3–4 or N1 disease who should be spared surgery.10 The poor outcomes following surgical resection alone and definitive chemoradiation alone led investigators to employ trimodality therapy consisting of neoadjuvant chemoradiation followed by esophagectomy to improve outcomes.
Updates in staging and pathologic evaluation of esophageal carcinoma following neoadjuvant therapy
2020, Annals of the New York Academy of Sciences
Conflict of interest: none.